In subgroup analyses stratified by the presence of diabetes, it is demonstrated that SGLT2 inhibitors provide consistent benefit on cardiovascular outcomes regardless of the baseline diabetes status. The gene discussed is SLC5A2; the disease is diabetes mellitus.